What You Ought to Know:
– PointClickCare introduced a collaboration with Pfizer Inc. to offer real-world insights for weak populations at excessive danger of age-related issues (together with Cachexia) – additional enhancing PCC’s mission to guard and help the senior inhabitants.
– With protection approaching 70% of the long-term and post-acute care (LTPAC) market, PointClickCare is uniquely positioned to offer life sciences firms, like Pfizer, with outcomes-based proof via in depth longitudinal affected person information. The continued collaboration between LTPAC and Life Sciences firms is powering this innovation.
Why It Issues
Globally, the inhabitants is getting older quickly. Between 2015 and 2050, the proportion of the world’s inhabitants over age 60 will almost double, from 12% to 22%. In america, the variety of people older than age 65 is projected to peak at 95 million in 2060. Many older adults might want to spend time in a long-term care facility as they age, however older adults in long-term care amenities are sometimes unable to take part in scientific trials. This lack of illustration can restrict the event of therapies aimed toward addressing the unmet wants of this essential inhabitants.
With entry to the real-world information PointClickCare can present, analysis and improvement groups can acquire a deeper understanding of the long-term and post-acute care demographic, leading to extra data-enriched scientific trials and empirical evidence-based research. To study extra about how our information is advancing care within the life sciences area, go to our web site right here.
